Update-1 11a EDT, Large cap drugs and biotechs resume slide on drug pricing “reform” from Trump threats.

  • IBB down 1.37%, XPH in downtrend tp $38.41.
  • Laggards holding BIB, GILD.
  • Winners losing MRK, RHHBY. LLY and PFE hit hard.
  • Gene therapy green: BOLD,SGMO.

Illumina (ILMN) whacked over 15%  on revenue warning,B of A downgrade.


Vacation Week-Biotech

Large cap sell-off

We will begin posting on a more regular basis after this vacation week. Biopharma equal weight (XBI) is holding up well about 10% above the May lows.NASDAQ (QQQ) is outperforming biotech sector. There is a lot of day to day volatility especially with smaller caps and upward momentum. Yesterday’s action was choppy. Here are several stocks to watch from our limited universe:

  • Gene therapy stocks with positive upward momentum near 52 week highs: BOLD, MGTX, QURE, RGNX, SRPT, VYGR.
  • Strong Mid-Cap biopharma stocks in 2019: ACAD,BPMC,GWPH, INCY, MRTX, NVCR, RGEN, XNCR .
  • Large caps are lagging in 2019 but MRK and RHHBY are best performers. Worst performers are: BIIB BMY GILD REGN .The IBB is barely holding SMA 20 levels. 9:55a EDT, PBMs up Large Cap pharma down after Trump Administration drops rebate overhaul plan (see news on right from Thompson Reuters.) And from AXIOS on drug pricing proposals.


Pin It on Pinterest